Instituto de Investigación Sanitaria Galicia Sur (IISGS)
Centro de investigación
Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas
Madrid, EspañaPublicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (54)
2024
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology and Therapeutics
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP
Journal of Clinical Medicine, Vol. 12, Núm. 14
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Increasing and sustaining blood-borne virus screening in Spain and Portugal throughout the COVID-19 pandemic: a multi-center quality improvement intervention
Frontiers in public health, Vol. 11, pp. 1268888
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
-
Role of Artificial Intelligence in Colonoscopy Detection of Advanced Neoplasias : A Randomized Trial
Annals of internal medicine, Vol. 176, Núm. 9, pp. 1145-1152
-
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders
Viruses, Vol. 14, Núm. 11
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
-
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection
Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 668-676
-
Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations
Future Virology, Vol. 17, Núm. 2, pp. 77-86
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
-
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851